Charles River Buys Immunology Player KWS BioTest for $20M

Media Coverage
red blood cells

FierceBiotech

Charles River Laboratories has snapped up British CRO KWS BioTest for £15 million ($20 million), enhancing its offerings in immuno-oncology and inflammatory and infectious diseases.

KWS specializes in offering in vitro and in vivo testing services in the larger area of immunology, including target identification and validation, lead optimization, in vivo disease models and clinical sample analysis.

“The addition of KWS strategically expands Charles River’s existing discovery capabilities in the field of immunology, which is critical given the importance of new therapies which harness the human immune system,” said Charles River chairman, president and CEO James Foster, in a statement.

Read the full article